Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Radiosurgery 20Magnetic Resonance Spectroscopy 20Exercise 15Biopsy 11Surveys and Questionnaires 9Standard of Care 9Cyclophosphamide 9Educational Status 8Practice Guidelines as Topic 7Doxorubicin 7Cisplatin 7Therapeutics 6Radiotherapy 6Methods 6Fluorodeoxyglucose F18 6Early Intervention, Educational 6Blood Specimen Collection 6Radiotherapy, Intensity-Modulated 5Electroporation 5Cryosurgery 5Colonoscopy 5X-Rays 4Water 4Vincristine 4Polymerase Chain Reaction 4Palliative Care 4Irinotecan 4Drug Therapy 4Diet Therapy 4Cryotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Withdrawn × oregovomab × Clear all
NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

GOG Foundation

Phase NA Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡